DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/36zr6q/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Mentioned
- Achaogen Inc.
- Adenium Biotech ApS
- AstraZeneca Plc
- ConjuGon, Inc.
- Da Volterra
- DexTech Medical AB
- Enteris BioPharma, Inc.
- GlaxoSmithKline Plc
- Melinta Therapeutics, Inc
- Merck & Co., Inc.
- MerLion Pharmaceuticals Pte Ltd
- Nabriva Therapeutics AG
- Nippon Shinyaku Co., Ltd.
- NovaBay Pharmaceuticals, Inc.
- Nymox Pharmaceutical Corporation
- Paratek Pharmaceuticals, Inc.
- Pivot Pharmaceuticals Inc
- Sequoia Sciences, Inc.
- Shionogi & Co., Ltd.
- Syntiron LLC
- The Medicines Company
- Zensun (Shanghai) Sci & Tech Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/36zr6q/urinary_tract
